175 related articles for article (PubMed ID: 1547417)
21. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
[TBL] [Abstract][Full Text] [Related]
22. Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes.
Saunders S; MacLeod ML; Salyers V; MacMillan PD; Ogborn MR
J Clin Nurs; 2013 Aug; 22(15-16):2206-15. PubMed ID: 23336392
[TBL] [Abstract][Full Text] [Related]
23. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
24. Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association.
Burke JR
Pediatr Nephrol; 1995 Oct; 9(5):558-61. PubMed ID: 8580009
[TBL] [Abstract][Full Text] [Related]
25. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
Dunn CJ; Wagstaff AJ
Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
[TBL] [Abstract][Full Text] [Related]
26. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin.
Zehnder C; Glück Z; Descoeudres C; Uehlinger DE; Blumberg A
Nephrol Dial Transplant; 1988; 3(5):657-60. PubMed ID: 3146724
[TBL] [Abstract][Full Text] [Related]
27. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
McNamee P; van Doorslaer E; Segaar R
Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
[TBL] [Abstract][Full Text] [Related]
28. Response to EPO therapy.
Bommer J
Przegl Lek; 1992; 49(1-2):36-7. PubMed ID: 1455003
[No Abstract] [Full Text] [Related]
29. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
30. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
[TBL] [Abstract][Full Text] [Related]
31. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
[TBL] [Abstract][Full Text] [Related]
32. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
[TBL] [Abstract][Full Text] [Related]
33. Cost of treating predialysis patients with recombinant human erythropoietin.
Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
Port RE; Kiepe D; Van Guilder M; Jelliffe RW; Mehls O
Clin Pharmacokinet; 2004; 43(1):57-70. PubMed ID: 14715051
[TBL] [Abstract][Full Text] [Related]
35. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
Fernández-Gallego J; Martín MA; Alonso A; Toledo R
Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
[No Abstract] [Full Text] [Related]
36. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
[TBL] [Abstract][Full Text] [Related]
37. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
Trivedi HS; Brooks BJ
Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous erythropoietin in the treatment of renal anaemia.
Drinovec J; Varl J
Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
[TBL] [Abstract][Full Text] [Related]
39. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
[TBL] [Abstract][Full Text] [Related]
40. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
Lui SF; Wong KC; Li PK; Lai KN
Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
